---
title: "Ascentage Pharma presents four-year follow-up data on Olverembatinib for TKI-resistant/intolerant CML-CP at ASH 2025, reaffirming long-term efficacy and safety in a registrational Phase II study."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269015493.md"
description: "Ascentage Pharma presented four-year follow-up data on Olverembatinib at ASH 2025, highlighting its long-term efficacy and safety for TKI-resistant/intolerant CML-CP patients. The findings were shared at the 67th American Society of Hematology Annual Meeting, reaffirming the drug's positive effects in a Phase II study."
datetime: "2025-12-09T00:47:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269015493.md)
  - [en](https://longbridge.com/en/news/269015493.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269015493.md)
---

# Ascentage Pharma presents four-year follow-up data on Olverembatinib for TKI-resistant/intolerant CML-CP at ASH 2025, reaffirming long-term efficacy and safety in a registrational Phase II study.

On December 8th, 2025, Ascentage Pharma Group International shared significant updates at the 67th American Society of Hematology Annual Meeting in Orlando, Florida. The company, listed on NASDAQ under AAPG and on HKEX as 6855, presented long-term findings from a four-year follow-up on a Phase II study of Olverembatinib. This study focused on patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP). The data displayed during a poster presentation underscored Olverembatinib's enduring positive effects and safety profile. The previous results were first revealed during an oral presentation at ASH 2023. Ascentage Pharma Group International is a global biopharmaceutical firm dedicated to developing innovative therapies for unmet medical needs in the realm of cancer treatment.

### Related Stocks

- [AAPGV.US](https://longbridge.com/en/quote/AAPGV.US.md)

## Related News & Research

- [Former Tesla Board Member Says xAI Can 'Break In With the Big Boys' Anthropic, OpenAI and Google— but There’s a Catch](https://longbridge.com/en/news/294967014.md)
- [Big Tech's $1.2 Trillion Hyperscaler AI Bet Could Ignite the Next Semiconductor ETF Rally](https://longbridge.com/en/news/294843392.md)
- [Lockup expiry will offer the next test of investor appetite for SpaceX shares](https://longbridge.com/en/news/294905336.md)
- [The Wegovy pill's 'surprise miss' is one reason Novo Nordisk's stock is down](https://longbridge.com/en/news/294862814.md)
- [ANALYSIS-Oracle Corp goes for high-stakes ratings gamble in AI strategy](https://longbridge.com/en/news/294853731.md)